Herpangina Treatment Market, by Virus (Coxsackie Virus A, Coxsackie Virus B, Enterovirus 71), by Symptoms (High Fever, Sore Throat, Blisters Or Ulcers In The Throat Mouth, Difficulty Swallowing, Loss Of Appetite, Headache, Neck Pain, Swollen Lymph Glands), by Treatment (Topical Anesthetics, Ibuprofen or Acetaminophen, Others) and, by End User (Hospitals, Homecare, Specialty Clinics, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

Herpangina is a viral infection that causes sores in the mouth. It is a very contagious disease that normally affects small children from 3 to 10 years of age, though adults and teenagers can also get it. Herpangina is caused by a virus and the most common viruses responsible are Echovirus, Coxsackie A16, Enterovirus 71, Coxsackie B. It is spread through saliva, respiratory droplets, stool or directly touching fluid from a sore. Symptoms can differ depending on which virus causes the infection. Herpangina is treated by controlling symptoms. The illness will be varied depending on the severity of the infection, the child’s age, and general health. As herpangina is a viral infection, antibiotics will not benefit.

COVID-19 Impact analysis

COVID-19 is an infectious disease that originated in Hubei province of the Wuhan city in China in late December. The highly contagious disease, caused by a virus, severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), is transmitted from human to human. Since the outbreak in December 2019, the disease has spread to almost 213 countries around the globe with the World Health Organization declaring it a public health emergency on March 11, 2020.

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future owing to the demand for vaccine and treatment drugs for COVID-19. This in turn is expected to have a significant impact on the herpangina treatment market.

Top Impacting Factors

• Increase in cases of herpangina viral infection and surge in pediatric populations drive the growth of the herpangina treatment market.
• In addition, increase in healthcare expenditure; availability of skilled professionals; rise in R&D activities to develop and launch the novel drugs in the market; are some factors, which boost the market growth for herpangina treatment.
• However, complications such as dehydration, aseptic meningitis, and neurological changes may occur, low birth weight and/or preterm delivery may occur in pregnant women who develop herpangina. Dehydration is another severe problem that may occur in some patients which is projected to hinder the market growth.
• Contrarily, favorable reimbursement policies and support from the government for regulatory approval present new pathways in the industry.

Key Benefits of the Report

• This study presents the analytical depiction of the herpangina treatment industry along with the current trends and future estimations to determine the imminent investment pockets.
• The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the herpangina treatment market share.
• The current market is quantitatively analyzed to highlight the herpangina treatment market growth scenario.
• Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
• The report provides a detailed herpangina treatment market analysis based on competitive intensity and how the competition will take shape in coming years

Questions answered in the herpangina treatment Report

• Which are the leading players active in the herpangina treatment market?
• What are the current trends that will influence the herpangina treatment market in the next few years?
• What are the driving factors, restraints, and opportunities of the herpangina treatment market?
• What future projections would help in taking further strategic steps?
• What is "Herpangina treatment"?
• What is "Herpangina treatment" Market prediction in the future?
• Who are the leading global players in the "Herpangina treatment" Market?
• What are the current trends and predicted trends?
• What are the key benefits of the "Herpangina treatment" Market report?

  Herpangina Treatment Market, by Virus Report Highlights

Aspects	Details
By Virus	Coxsackie Virus A Coxsackie Virus B Enterovirus 71
By Symptoms	High Fever Sore Throat Blisters Or Ulcers In The Throat & Mouth Difficulty Swallowing Loss Of Appetite Headache Neck Pain Swollen Lymph Glands
By Treatment	Topical Anesthetics Ibuprofen or Acetaminophen Others
By End User	Hospitals Homecare Specialty Clinics Others
By Region	North America  (U.S., Canada, Mexico) Europe  (France, Germany, Italy, Spain, UK, Rest of Europe) Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific) LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players	GlaxoSmithKline Plc, Sanofi S.A, ViiV Healthcare group of companies, Gilead Sciences, Inc., Novartis AG, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., AbbVie Inc., Vertex Pharmaceuticals Incorporated, Johnson and Johnson Services, Inc., Mitsubishi Tanabe Pharma Corporation, Pfizer Inc.

^*Terms and Conditions Apply